Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.07 USD -1.83% Market Closed
Market Cap: 197m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nektar Therapeutics
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Total Other Income
-$6.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Total Other Income
-$195m
CAGR 3-Years
N/A
CAGR 5-Years
33%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Total Other Income
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Total Other Income
$1.1B
CAGR 3-Years
42%
CAGR 5-Years
205%
CAGR 10-Years
-1%
Eli Lilly and Co
NYSE:LLY
Total Other Income
$439.4m
CAGR 3-Years
-18%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
197.4m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.67 USD
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Total Other Income?
Total Other Income
-6.5m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Total Other Income amounts to -6.5m USD.

Back to Top